Histone deacetylases (HDACs) are emerging as exciting new targets for drug development, particularly for cancer and metabolic diseases. Because they exert control over gene transcription and ...

Though there are four histone deacetylase (HDAC) inhibitors that are FDA approved to treat some forms of lymphoma, there’s less evidence for their efficacy in solid tumors. Now, new findings in mice ...

A beleaguered class of epigenetic modulators continues to struggle for oncology success, but new insights into their mechanisms in cancer may yet offer hope. In February the US Food and Drug ...

As gene regulation changes in Alzheimer’s disease, scientists believe that histone deacetylases (HDACs) go into overdrive, shutting down transcription of certain genes. Consequently, several research ...

Most pancreatic tumors are surrounded by a thick, nearly impenetrable wall of fibrosis— scar tissue—that makes it hard for drugs to access and destroy the cancer cells. Researchers at the Salk ...

DelveInsight’s 'HDAC Inhibitor Pipeline Insight 2023' report provides comprehensive global coverage of pipeline HDAC inhibitors in various stages of clinical development, major pharmaceutical ...

Epigentic mechanisms help to regulate proinflammatory cytokine production and, thus, might be important in the pathogenesis of rheumatoid arthritis (RA). Histone deacetylases (HDACs) remove acetyl ...

Solid tumor patients with G12V and G13D KRAS aberrations have poor survival following ICI treatment. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not ...

Histone deacetylase (HDAC) antibodies are used to study the process of histone deacetylation, an essential activity that happens within human cells. Numerous assays currently exist that rely on the ...

Pancreatic cancer is one of the deadliest cancers - only about one in eight patients survives five years after diagnosis. Those dismal statistics are in part due to the thick, nearly impenetrable wall ...